



CLINICAL INSIGHTS

EXCEL Division of Blue Cross Laboratories

P-PPI TABLETS

Issue IX, No.29, 2026

Real-world safety and effectiveness of pantoprazole 40 mg in patients with heartburn: A large-scale, multicentric, retrospective post-marketing surveillance study from India

Sandeep MS et.al; International Journal of Gastroenterology Research. 2026; 8(1): 54-61

- Pantoprazole is a widely prescribed proton pump inhibitor for managing heartburn and gastroesophageal reflux disease. Although controlled trials have established its efficacy, large-scale real-world evidence from diverse Indian populations remains limited. This post-marketing surveillance study evaluated the safety and effectiveness of pantoprazole 40 mg tablets in routine clinical practice.
- This retrospective, multicentric, real-world observational study was conducted at 3,112 sites across India. It included adults aged 18–65 years with heartburn who received pantoprazole 40 mg once daily for 8 weeks.
- Of the 20,218 records collected, 18,718 were valid and included in the analysis. Safety was evaluated based on the incidence, severity, causality, duration, and outcomes of adverse drug reactions. Effectiveness & tolerability were rated on a five-point global scale: excellent, very good, good, fair, or poor.
- Effectiveness was rated excellent or very good in 88.2% of patients. Adverse drug reactions were mild in severity, with complete resolution in 100% of cases. Causality assessment classified 47.7% of events as certain and 52.3% as unlikely. Tolerability was rated excellent or very good in 89.4% of patients.

These findings support the use of pantoprazole 40 mg in routine clinical practice for the management of heartburn and acid-related disorders across diverse patient populations in India.

